{
    "title": "115_s252",
    "content": "The \"Medicare Drug Savings Act of 2017\" requires drug manufacturers to provide rebates for drugs dispensed to low-income individuals. The \"Medicare Drug Savings Act of 2017\" mandates drug manufacturers to offer rebates for drugs given to low-income individuals. Section 1860D-2 of the Social Security Act is amended to include a new subsection (f) requiring a Prescription Drug Rebate Agreement for Rebate Eligible Individuals starting in 2019. This agreement excludes drugs from manufacturers without a rebate agreement. The Medicare Drug Savings Act of 2017 mandates drug manufacturers to offer rebates for drugs given to low-income individuals. A manufacturer not entering a rebate agreement for 2018 will have their product excluded as a 'covered part D drug' for the following year. The rebate agreement requires manufacturers to provide rebates for covered drugs dispensed to rebate eligible individuals after December 31, 2017. The rebate agreement mandates drug manufacturers to provide rebates for drugs dispensed to low-income individuals. Manufacturers must pay the rebate to the Secretary within 30 days of receiving the required information. The Secretary will establish terms and conditions for compliance, penalties, and program evaluations similar to rebate agreements under previous paragraphs. The rebate agreement requires drug manufacturers to provide rebates for drugs dispensed to low-income individuals. Manufacturers must pay the rebate to the Secretary within 30 days. Terms and conditions for rebate agreements are specified under paragraphs (3) and (4) of section 1927(b). The rebate agreement mandates drug manufacturers to provide rebates for drugs dispensed to low-income individuals, including payments for low-income and reinsurance subsidies. Medicaid rebate amount is defined as the difference between the Medicaid rebate amount and the average Medicare drug program rebate eligible rebate amount for a specific form, strength, and period. The Medicaid rebate amount is the specified amount for different types of drugs provided by manufacturers for a rebate period, as outlined in the rebate agreement. The term 'average Medicare drug program rebate eligible rebate amount' refers to the total rebates, discounts, or price concessions for each dosage form and strength of a covered part D drug provided by a manufacturer for a rebate period. The average Medicare drug program rebate eligible rebate amount is the total rebates, discounts, or price concessions for each dosage form and strength of a covered part D drug provided by a manufacturer for a rebate period. This applies equally to drugs dispensed to rebate eligible Medicare drug plan enrollees and drugs dispensed to PDP and MA-PD enrollees who are not rebate eligible individuals. The average Medicare drug program rebate eligible rebate amount is calculated by dividing the number of units of a drug dispensed to rebate eligible individuals in specific plans by the total number of units dispensed to all rebate eligible individuals in all plans. The Secretary may establish a methodology for estimating average Medicare drug program rebate eligible rebate amounts based on bid and utilization information, using these estimates to determine rebates. A reconciliation process for adjusting manufacturer rebate payments must be established within 3 months of manufacturers receiving the information. The Secretary may establish a methodology for estimating average Medicare drug program rebate eligible rebate amounts based on bid and utilization information, using these estimates to determine rebates. A reconciliation process for adjusting manufacturer rebate payments must be established within 3 months of manufacturers receiving the information. The provisions of paragraph (4) of section 1927(b) shall apply to rebate agreements under this subsection, and the Secretary shall establish other terms and conditions of the rebate agreement related to compliance. The term 'rebate period' is defined in section 1927(k)(8) and applies to subsidy eligible individuals under the Medicare drug program. For contract years starting on or after January 1, 2019, PDP sponsors must comply with reporting requirements for determining and paying rebates related to Medicare drug plan enrollees. PDP sponsors must report information on drug units, prices, discounts, and rebates to manufacturers for Medicare drug plan enrollees. PDP sponsors must report information on drug units, prices, discounts, and rebates to manufacturers for Medicare drug plan enrollees, including details on price discounts, concessions, and rebates for different enrollees. Additional information may be required by the Secretary to calculate average rebate amounts and determine required rebates for specific drugs. PDP sponsors must report drug information to the Secretary for audit oversight and evaluation, following a standard reporting format. Confidentiality provisions apply to the information reported, similar to those for manufacturers and wholesalers. The paragraph discusses the oversight of information reported by PDP sponsors to the Secretary, allowing the Inspector General of the Department of Health and Human Services to use the information for audit, investigation, and evaluations. The paragraph outlines penalties for PDP sponsors who fail to provide timely information or provide false information, including civil money penalties of $10,000 per day for late information and up to $100,000 for each item of false information. The paragraph discusses civil money penalties for PDP sponsors who fail to provide timely or accurate information, with penalties outlined in section 1128A. Additionally, it mentions a reporting requirement related to rebates for Medicare drug plan enrollees and the deposit of rebates into the Medicare Prescription Drug Account. Section 1860D-16(c) of the Social Security Act is amended to include a rebate provision for Medicare drug plan enrollees. This amendment excludes rebate amounts from the determination of best price and average manufacturer price under Medicaid. The Social Security Act is amended to include a rebate provision for Medicare drug plan enrollees, excluding rebate amounts from best price and average manufacturer price determinations under Medicaid. Additionally, amounts paid under rebate agreements are specified in the amendment."
}